Azithromycin for COVID-19: What Do Clinical Trials Show?

Why was azithromycin investigated as a COVID-19 treatment?

Azithromycin is a macrolide antibiotic with additional effects on inflammatory responses. Early laboratory findings provided a rationale for testing it against COVID-19, but those findings could not establish whether patients would recover faster or survive more often. That distinction made randomized clinical trials essential. The investigators described this rationale in the [RECOVERY trial publication](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884931/).

Prescribing also reflected diagnostic uncertainty. CDC reports that almost 80% of patients hospitalized with COVID-19 received an antibiotic between March and October 2020. Ceftriaxone was frequently prescribed alongside azithromycin, a pattern CDC linked to difficulties distinguishing COVID-19 from community-acquired pneumonia at admission. These historical prescribing figures describe antibiotic exposure; they do not establish how many patients needed treatment for bacteria. [CDC's pandemic resistance overview](https://www.cdc.gov/antimicrobial-resistance/data-research/threats/covid-19.html).

What did randomized trials find about azithromycin?

The RECOVERY comparison included 7,763 hospitalized patients: 2,582 assigned azithromycin and 5,181 assigned usual care. Death within 28 days occurred in approximately 22% of each group, with no statistically significant difference. Researchers also found no significant improvement in discharge or in the combined outcome of invasive ventilation or death among participants who were not already invasively ventilated. These results did not support adding azithromycin specifically to treat COVID-19. [RECOVERY results](https://pmc.ncbi.nlm.nih.gov/articles/PMC7884931/).

The PRINCIPLE trial addressed a different setting: people with suspected COVID-19 receiving community care who were at increased risk of complications. It found little evidence that azithromycin produced a clinically meaningful improvement in recovery time. Hospital admissions occurred in approximately 3% of participants in each comparison group. Together, the trials support avoiding routine azithromycin for COVID-19 itself, while leaving its established role in appropriate bacterial infections intact. [PRINCIPLE results](https://www.sciencedirect.com/science/article/pii/S014067362100461X).

When are antibiotics appropriate for someone with COVID-19?

WHO's June 2025 guideline recommends against empirical antibiotics for non-severe COVID-19 when clinical suspicion of a concurrent bacterial infection is low. It also suggests avoiding them in severe COVID-19 under the same condition, although that recommendation is conditional. Empirical treatment means starting antibiotics on clinical grounds before the bacterial cause is established. Disease severity alone therefore does not automatically establish a need for antibiotics. [WHO clinical management guidance](https://www.who.int/publications/i/item/B09467).

Assessment can change during an illness. WHO emphasizes considering the patient's history, examination and laboratory findings, with reassessment as the clinical situation evolves. Its recommendation does not apply when suspicion of bacterial infection is no longer low. The practical implication is to evaluate the reason for antibiotic treatment rather than treating a positive COVID-19 test as sufficient justification. [WHO's detailed antibiotic recommendations](https://iris.who.int/bitstream/handle/10665/381920/B09467-eng.pdf?sequence=1).